Anti-tumour necrosis factor agents and lipid profile: a class effect?

Ann Rheum Dis. 2008 Jun;67(6):895-6. doi: 10.1136/ard.2007.078287.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Atherosclerosis / metabolism
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Lipid Metabolism*
  • Lymphotoxin-alpha / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Rheumatic Diseases / drug therapy*
  • Rheumatic Diseases / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Lymphotoxin-alpha
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept